{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:14:40Z","timestamp":1792815280913,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010535","name":"Actinium Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010535","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41375-025-02528-3","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:46:41Z","timestamp":1739627201000},"page":"837-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-4766","authenticated-orcid":false,"given":"Sameem M.","family":"Abedin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-2611","authenticated-orcid":false,"given":"Guru Subramanian","family":"Guru Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1798-9658","authenticated-orcid":false,"given":"Laura C.","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen-Sue","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Runaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Gauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash G.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate L.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojisola","family":"Rotibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Vusirikala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab L.","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"2528_CR1","doi-asserted-by":"crossref","unstructured":"Koenig K, Mims A, Levis MJ, Horowitz MM. The changing landscape of treatment in acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1\u201312.","DOI":"10.1200\/EDBK_279129"},{"key":"2528_CR2","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101240","volume":"34","author":"EL Atallah","year":"2021","unstructured":"Atallah EL. Why isn\u2019t there a one-size-fits-all approach for relapsed\/refractory acute myeloid leukemia? Insights into different variables for decision-making. Best Pract Res Clin Haematol. 2021;34:101240.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2528_CR3","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2016.148825","volume":"101","author":"P Ferguson","year":"2016","unstructured":"Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, et al. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. Haematologica. 2016;101:1351\u20138.","journal-title":"Haematologica"},{"key":"2528_CR4","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/HS9.0000000000000572","volume":"5","author":"F Thol","year":"2021","unstructured":"Thol F, Heuser M. Treatment for relapsed\/refractory acute myeloid leukemia. Hemasphere. 2021;5:e572.","journal-title":"Hemasphere"},{"key":"2528_CR5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","volume":"33","author":"X Chen","year":"2015","unstructured":"Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258\u201364.","journal-title":"J Clin Oncol"},{"key":"2528_CR6","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","volume":"28","author":"TL Rosenblat","year":"2022","unstructured":"Rosenblat TL, McDevitt MR, Carrasquillo JA, Pandit-Taskar N, Frattini MG, Maslak PG, et al. Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator actinium-225-lintuzumab. Clin Cancer Res. 2022;28:2030\u20137.","journal-title":"Clin Cancer Res"},{"key":"2528_CR7","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A, Kramer M, R\u00f6llig C, Thiede C, Bornh\u00e4user M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer Journal. 2014;4:e218\u2013e.","journal-title":"Blood Cancer Journal"},{"key":"2528_CR8","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O\u2019Connor J, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23:4110\u20136.","journal-title":"J Clin Oncol"},{"key":"2528_CR9","doi-asserted-by":"crossref","first-page":"e1566","DOI":"10.6061\/clinics\/2020\/e1566","volume":"75","author":"WFD Silva","year":"2020","unstructured":"Silva WFD, Rosa LID, Seguro FS, Silveira DRA, Bendit I, Buccheri V, et al. Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience. Clinics (Sao Paulo). 2020;75:e1566.","journal-title":"Clinics (Sao Paulo)"},{"key":"2528_CR10","doi-asserted-by":"crossref","first-page":"e12102","DOI":"10.1097\/MD.0000000000012102","volume":"97","author":"J Xu","year":"2018","unstructured":"Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study. Medicine (Baltimore). 2018;97:e12102.","journal-title":"Medicine (Baltimore)"},{"key":"2528_CR11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","volume":"35","author":"SL Price","year":"2011","unstructured":"Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011;35:301\u20134.","journal-title":"Leuk Res"},{"key":"2528_CR12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","volume":"80","author":"A Wierzbowska","year":"2008","unstructured":"Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Ho\u0142owiecki J, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80:115\u201326.","journal-title":"Eur J Haematol"},{"key":"2528_CR13","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2018.204792","volume":"104","author":"AB Halpern","year":"2019","unstructured":"Halpern AB, Megan O, Emily MH, Bart LS, Paul CH, Mary-Elizabeth MP, et al. Phase I\/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed\/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica. 2019;104:e143\u2013e6.","journal-title":"Haematologica"},{"key":"2528_CR14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2528_CR15","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"2528_CR16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/10428194.2020.1821009","volume":"62","author":"MU Mushtaq","year":"2021","unstructured":"Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, et al. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed\/refractory acute myeloid leukemia. Leuk Lymphoma. 2021;62:158\u201366.","journal-title":"Leuk Lymphoma"},{"key":"2528_CR17","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.26941","volume":"98","author":"NG Daver","year":"2023","unstructured":"Daver NG, Iqbal S, Huang J, Renard C, Lin J, Pan Y, et al. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol. 2023;98:1176\u201384.","journal-title":"Am J Hematol"},{"key":"2528_CR18","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106:894\u20138.","journal-title":"Haematologica"},{"key":"2528_CR19","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","volume":"108","author":"N Gangat","year":"2023","unstructured":"Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, et al. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica. 2023;108:3170\u20134.","journal-title":"Haematologica"},{"key":"2528_CR20","first-page":"1000038","volume":"1","author":"KK Chin","year":"2024","unstructured":"Chin KK, Valtis Y, Derkach A, Salman MY, Boussi L, Ciervo J, et al. Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia. Blood Neoplasia. 2024;1:1000038.","journal-title":"Blood Neoplasia"},{"key":"2528_CR21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2022-157827","volume":"140","author":"S Abedin","year":"2022","unstructured":"Abedin S, Guru Murthy GS, Szabo A, Hamadani M, Michaelis LC, Carlson K-S, et al. Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R\/R AML with Adverse Features. Blood. 2022;140:157\u20138.","journal-title":"Blood"},{"key":"2528_CR22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/16078454.2021.2013410","volume":"27","author":"Y Guo","year":"2022","unstructured":"Guo Y, Deng L, Qiao Y, Liu B. Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis. Hematology. 2022;27:53\u201364.","journal-title":"Hematology"},{"key":"2528_CR23","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","volume":"142","author":"SD Freeman","year":"2023","unstructured":"Freeman SD, Thomas A, Thomas I, Hills RK, Vyas P, Gilkes A, et al. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial. Blood. 2023;142:1697\u2013707.","journal-title":"Blood"},{"key":"2528_CR24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12185-013-1365-1","volume":"97","author":"A Takeshita","year":"2013","unstructured":"Takeshita A. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia. Int J Hematol. 2013;97:703\u201316.","journal-title":"Int J Hematol"},{"key":"2528_CR25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29:369\u201377.","journal-title":"J Clin Oncol"},{"key":"2528_CR26","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","volume":"119","author":"JA Pollard","year":"2012","unstructured":"Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119:3705\u201311.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02528-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02528-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02528-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T09:47:07Z","timestamp":1744019227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02528-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02528-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5368989\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M.A. received consultancy fees from Incyte Inc, Servier, and Soba; and received research funding from Actinium, AltruBio, and Incyte. G.S.G.M. received consultancy and speaker bureau fees from Amgen; speaker bureau fees from Rigel; advisory board fees from Pfizer, BMS, Autolus, Syndax and Stemline; and research funding from LOXO\/Lilly, Zentalis, Schrodinger, and Merck. M.H. received consultancy, research funding and speaker bureau fees from ADC Therapeutics; research funding from Spectrum Pharmaceuticals and Astellas Pharma; consultancy and speaker bureau fees from Kite Pharma; speaker bureau fees from Sanofi Genzyme, AstraZeneca and BeiGene; and consultancy fees from Omeros, BMS, Genmab, CRISPR, Allovir, Caribou, Autolus, Forte Biosciences, AbbVie, and Byondis. L.C.M. received consultancy fees from Disc Medicine. K.S.M., L.R., and K.G. have no conflicts of interest to disclose. A.G.D., M.M.C., K.L.L., M.R., U.S., and M.V. are currently employed by Actinium Pharmaceuticals and hold equity in this publicly traded company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}